Therapeutic impact of Nintedanib with paclitaxel and/or a PD-L1 antibody in preclinical models of orthotopic primary or metastatic triple negative breast cancer

Therapeutic impact of Nintedanib with paclitaxel and/or a PD-L1 antibody in preclinical models of orthotopic primary or metastatic triple negative breast cancer

Abstract Background Triple negative breast cancer (TNBC) is an aggressive malignancy with poor prognosis, in part because of the current lack of any approved molecularly targeted therapy. We evaluated various combinations of three different drugs: nintedanib, an antiangiogenic TKI targeting VEGF rec...

Full description

Bibliographic Details
Main Authors: Elaine Reguera-Nuñez, Ping Xu, Annabelle Chow, Shan Man, Frank Hilberg, Robert S. Kerbel
Format: Article
Language:English
Published: BMC 2019-01-01
Series:Journal of Experimental & Clinical Cancer Research
Subjects:
VEGF
Antiangiogenic drugs
Chemotherapy
Immune checkpoint therapy
PD-L1
Metastasis
Online Access:http://link.springer.com/article/10.1186/s13046-018-0999-5

Internet

http://link.springer.com/article/10.1186/s13046-018-0999-5

Similar Items